Galderma Group AGXSWX:GALD -1.02%15 PS Ratio is 10.33 as of Jul. 01, 2026, which is 54% above its 10-year median of 6.69. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 949 Drug Manufacturers companies, Galderma Group AG ranks worse than 87.04% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Galderma Group AG's share price is CHF183.90.
Galderma Group AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.80. Hence, Galderma Group AG's PS Ratio for today is 10.33.
Warning Sign:
Galderma Group AG stock PS Ratio (=10.11) is close to 3-year high of 10.11.
The historical rank and industry rank for Galderma Group AG's PS Ratio or its related term are showing as below:
XSWX:GALD'
s PS Ratio Range Over the Past 10 Years
Min: 4.16 Med: 6.69 Max: 10.44
Current: 10.33
During the past 5 years, Galderma Group AG's highest PS Ratio was 10.44. The lowest was 4.16. And the median was 6.69.
XSWX:GALD's PS Ratio is ranked worse than 87.04% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs XSWX:GALD: 10.33
During the past 5 years, Galderma Group AG's highest 3-Year average Revenue per Share Growth Rate was 7.60% per year. The lowest was 5.50% per year. And the median was 6.55% per year.
Back to Basics: PS Ratio
Galderma Group AG (XSWX:GALD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Galderma Group AG PS Ratio Related Terms
Galderma Group AG PS Ratio Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Galderma Group AG's Share Price of today is CHF183.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Galderma Group AG (XSWX:GALD) has a PS Ratio of 10.33 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Galderma Group AG and its competitors. This is 54% above median its historical median of 6.69. Over the past decade, Galderma Group AG's PS Ratio has ranged from 4.16 to 10.44. According to the industry distribution chart, Galderma Group AG ranks #826 out of 949 companies in the Drug Manufacturers industry, placing it in the top 87%.
Is Galderma Group AG's PS Ratio too high?
Galderma Group AG's current PS Ratio of 10.33 is 54% above median its 10-year median of 6.69. Over the past 10 years, this metric has ranged from a low of 4.16 to a high of 10.44. The Drug Manufacturers industry median PS Ratio is 2.28. Galderma Group AG's value of 10.33 is 353.1% above this industry median. Based on the distribution chart, Galderma Group AG ranks #826 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #826 out of 949 companies for PS Ratio. This places Galderma Group AG in the lower half of its industry. The industry median PS Ratio is 2.28. Galderma Group AG's value of 10.33 is 353.1% above this benchmark. Historically, Galderma Group AG's own PS Ratio has ranged from 4.16 to 10.44 over the past decade. While the company's 10-year median is 6.69 vs. the industry median of 2.28, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current PS Ratio of 10.33 is 353.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current PS Ratio is 10.33, which is 54% above median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current PS Ratio of 10.33. The current PS Ratio is 10.33, which is 54% above median its 10-year median of 6.69 and 353.1% above the Drug Manufacturers industry median of 2.28. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current PS Ratio is 10.33 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 